Sciele to acquire Addrenex for $29 million
Sciele Pharma will pay $29 million in cash for Addrenex Pharmaceuticals, in a transaction which builds on a series of product licensing deals between the two US firms over the past few years.
Sciele Pharma will pay $29 million in cash for Addrenex Pharmaceuticals, in a transaction which builds on a series of product licensing deals between the two US firms over the past few years.